Skip to main content
. 2012 Sep 28;287(47):39812–39823. doi: 10.1074/jbc.M112.406520

FIGURE 2.

FIGURE 2.

p38 maintains high basal activation of c-Met. A, Western blot analysis of phosphorylated c-Met in human cholangiocarcinoma cell lines. B and C, p38 inhibition decreases phosphorylated c-Met. After treatment with various doses of SB203580 (SB) for 12 h (B) or treatment with SB203580 (SB, 10 μm) for the indicated time periods (C), QBC939, RBE, and HCCC-9810 cells were subjected to Western blot analysis. D, p38 siRNA decreases phosphorylated c-Met. After transfection with p38 siRNA for 60 h, QBC939, RBE, and HCCC-9810 cells were subjected to Western blot analysis. E, Western blot analysis of phosphorylated c-Met and p38 in human hepatocellular carcinoma cell lines. F, p38 inhibition decreases phosphorylated c-Met in MHCC-97H cells. After treatment with SB203580 (10 μm) for the indicated time periods, MHCC-97H cells were subjected to Western blot analysis. G, constitutively active MKK6 increases phosphorylated c-Met in HGF-treated HepG2 cells. After HGF (0.02 mg) treatment for 1 h with or without MKK6 pro-transfection for 24 h, serum-starved HepG2 cells were subjected to Western blot analysis.